Centessa Pharmaceuticals plc CNTA
Updated: 13 Sep 2026
No signal published yet
We already track Centessa Pharmaceuticals and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Centessa Pharmaceuticals plc? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Centessa Pharmaceuticals free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
Eli Lilly and Company completed its acquisition of Centessa Pharmaceuticals on June 24, 2026, paying $38.00 per share in cash plus a contingent value right. The transaction valued Centessa at approximately $7.8 billion and resulted in the delisting of its shares from Nasdaq.
What Firelda Watch includes for Centessa Pharmaceuticals plc
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Centessa Pharmaceuticals plc? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Centessa Pharmaceuticals free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more